文献速递免疫规划

基于短发夹RNA靶向NF-κB抑制蛋白IκBα的佐剂促进真皮树突状细胞向引流淋巴结迁移并增强DNA疫苗接种诱导的抗肿瘤CTL反应

A short hairpin RNA-based adjuvant targeting NF-κB repressor IκBα promotes migration of dermal dendritic cells to draining lymph nodes and antitumor CTL responses induced by DNA vaccination.
PubMed 文献 · Vaccine · 2017-06-27

该临床前研究测试了沉默IκBα的shRNA质粒(shIκBα)作为DNA疫苗佐剂的效果。体外实验显示shIκBα可降低IκBα表达并促进NF-κB驱动转录,体内可上调炎症靶基因。皮内DNA电穿孔可诱导皮肤迁移性树突状细胞向引流淋巴结迁移及真皮树突状细胞成熟,shIκBα进一步促进成熟皮肤迁移性树突状细胞(尤其真皮树突状细胞)的迁移。与编码黑色素瘤相关抗原TRP2的质粒联用时,小鼠中TRP2特异性CTL反应增强,B16F10细胞静脉攻击后肺部黑色素瘤病灶数减少,治疗性接种可延缓B16F10皮下肿瘤生长。

要点

  • shIκBα质粒在体外降低IκBα表达并促进NF-κB驱动转录,体内上调炎症靶基因。
  • shIκBα促进成熟皮肤迁移性树突状细胞(尤其真皮树突状细胞)向引流淋巴结迁移。
  • pTRP2联合shIκBα增强TRP2特异性CTL反应、减少B16F10肺转移灶并延缓皮下肿瘤生长。

核心结论

  • 促进NF-κB激活的佐剂是增强DNA疫苗诱导的DC激活及肿瘤保护性CTL反应的有吸引力的策略。

研究设计与样本

  • 临床前模型研究,包含体外实验与小鼠体内实验。

主要发现

  • shIκBα质粒在体外降低IκBα表达、促进NF-κB驱动转录,在体内上调炎症靶基因。
  • 皮内DNA电穿孔诱导皮肤迁移性树突状细胞向引流淋巴结迁移及真皮树突状细胞成熟,shIκBα进一步促进成熟皮肤迁移性树突状细胞(尤其真皮树突状细胞)的迁移。
  • pTRP2联合shIκBα的小鼠中TRP2特异性CTL反应增强,B16F10细胞静脉攻击后肺部黑色素瘤病灶数减少。
  • 治疗性接种pTRP2联合shIκBα延缓B16F10皮下黑色素瘤生长。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DNA vaccination is an attractive approach to elicit tumor-specific cytotoxic CD8+ T lymphocytes (CTL), which can mediate protective immunity against tumors. To initiate CTL responses, antigen-encoding plasmids employed for DNA vaccination need to activate dendritic cells (DC) through the stimulation of DNA-sensing innate immune receptors that converge in the activation of the master transcription factor NF-κB. To this end, NF-κB repressor IκBα needs to be degraded, allowing NF-κB to translocate to the nucleus and transcribe proinflammatory target genes, as well as its repressor IκBα. Therefore, NF-κB activation is self-limited by de novo synthesis of IκBa, which sequesters NF-κB in the cytosol. Hence, we tested whether co-delivering a shRNA-based adjuvant able to silence IκBα expression would further promote DNA-induced NFκB activation, DC activation and tumor-protective CTL responses induced by DNA vaccination in a preclinical model. First, an IκBα-targeting shRNA plasmid (shIκBα) was shown to reduce IκBα expression and promote NFκB-driven transcription in vitro, as well as up-regulate inflammatory target genes in vivo. Then, we showed that intradermal DNA electroporation induced the migration of skin migratory dendritic cells to draining lymph nodes and maturation of dermal dendritic cells (dDC). Interestingly, shIκBα further promoted the migration of mature skin migratory dendritic cells, in particular dDC, which are specialized in antigen cross-presentation and activation of CD8+ T cells. Consistently, mice vaccinated with a plasmid encoding the melanoma-associated antigen tyrosinase-related protein 2 (TRP2) in combination with shIκBα enhanced TRP2-specific CTL responses and reduced the number of lung melanoma foci in mice challenged with intravenous injection of B16F10 cells. Moreover, therapeutic vaccination with pTRP2 and shIκBα delayed the growth of B16F10 melanoma subcutaneous tumors. Our data suggest that adjuvants promoting NF-κB activation represent an attractive strategy to boost DC activation and promote the generation of tumor-protective CTL responses elicited by DNA vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Gálvez-Cancino F, Roco J, Rojas-Colonelli N, et al. A short hairpin RNA-based adjuvant targeting NF-κB repressor IκBα promotes migration of dermal dendritic cells to draining lymph nodes and antitumor CTL responses induced by DNA vaccination. Vaccine. 2017. PMID: 28666759. doi:10.1016/j.vaccine.2017.06.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。